Patient-derived organoids in disease modelling
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
This article discusses the need for adulticidal drugs to treat Onchocerca volvulus infections, a parasite causing onchocerciasis (river blindness), as the current treatment with ivermectin and surgery presents challenges for affected communities. It highlights research findings on the potential of analgesic medicines to target adult worms and emphasises the importance…
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
As the NHS celebrates its 75th anniversary, healthcare leaders, policymakers, and practitioners have been sharing their innovative ideas on how to reshape and safeguard its future.
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to…
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery.
Researchers have important implications for the ongoing fight against malaria, a disease that affects approximately 247 million individuals and causes over 619,000 deaths each year, predominantly among young children.